FDA Market Authorization for BONESUPPORT’s CERAMENT G

BONESUPPORT Cerament G Bone Graft Substitute

BONESUPPORT received market authorization from FDA for the company's antibiotic eluting product CERAMENT G, for the indication bone infection (osteomyelitis).

CERAMENT G previously received Breakthrough Device Designation in 2021. As what is reportedly the first injectable combination antibiotic bone graft substitute, CERAMENT G can be...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0